ID: ALA4458672

Max Phase: Preclinical

Molecular Formula: C19H17ClN8S2

Molecular Weight: 456.99

Molecule Type: Unknown

Representations

Canonical SMILES:  C#CCSc1nc(Sc2nnnn2CCN(C)C)c(C#N)c(-c2cccc(Cl)c2)n1

Standard InChI:  InChI=1S/C19H17ClN8S2/c1-4-10-29-18-22-16(13-6-5-7-14(20)11-13)15(12-21)17(23-18)30-19-24-25-26-28(19)9-8-27(2)3/h1,5-7,11H,8-10H2,2-3H3

Standard InChI Key:  PEUFTIXWXRALOL-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 456.99

Molecular Weight (Monoisotopic): 456.0706

AlogP: 3.09

#Rotatable Bonds: 8

Polar Surface Area: 96.41

Molecular Species: NEUTRAL

HBA: 10

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 8.33

CX LogP: 4.84

CX LogD: 3.86

Aromatic Rings: 3

Heavy Atoms: 30

QED Weighted: 0.22

Np Likeness Score: -2.66

References

1. Zhou W, Ma L, Ding L, Guo Q, He Z, Yang J, Qiao H, Li L, Yang J, Yu S, Zhao L, Wang S, Liu HM, Suo Z, Zhao W..  (2019)  Potent 5-Cyano-6-phenyl-pyrimidin-Based Derivatives Targeting DCN1-UBE2M Interaction.,  62  (11): [PMID:31157974] [10.1021/acs.jmedchem.9b00003]

Source

Source(1):

• Scientific Literature